Classically, type 1 diabetes has been diagnosed only after patients have lost a critical threshold of beta cell mass, resulting in symptoms of hyperglycemia due to insulin deficiency. Despite advances in glycemic monitoring and insulin delivery, patients with clinical type 1 diabetes experience enormous mental burden and health care costs and are at risk of developing complications from chronic hyper or hypoglycemia.
Natural history studies have shown that type 1 diabetes can be diagnosed in presymptomatic stages via detection of 2 or more islet autoantibodies. Stage 1 is defined by the presence of 2 or more islet autoantibodies with normoglycemia and stage 2 by the presence of 2 or more islet autoantibodies and abnormal glucose metabolism.
Stage 3 marks the clinical diagnosis of type 1 diabetes, characterized by hyperglycemia. Options for disease modification to intervene in the presymptomatic stages and delay insulin requirements are becoming available clinically or through prevention trials testing agents shown to have efficacy in stage 3 disease (NCT07222137 and NCT07216391).
JAMA (Journal of the American Medical Association) published a clinical update in Research Highlights on 16 Jun 2026.
The item focuses on A New Type 1 Diabetes Diagnosis Paradigm.
Review the original article for the full source wording and details.